

# BEST OF ASCO®

OFFICIALLY LICENSED



JUNE  
**23-24**

**THE WESTIN LIMA HOTEL**  
C/ Las Begonias 450,  
San Isidro

Presential  
*streaming*

■ [www.spomedica.org](http://www.spomedica.org)



Foto: Víctor Romero Valladares (Flickr)

VÁLIDO PARA  
RECERTIFICACIÓN MÉDICA: 3.0 PUNTOS





## **Paola Montenegro Beltrán, MD**

President

Con gran entusiasmo, les damos la más cordial bienvenida al Congreso Científico Best of ASCO (American Society of Clinical Oncology), organizado por la Sociedad Peruana de Oncología Médica en la ciudad de Lima.

El congreso Best of ASCO es un espacio dedicado al intercambio de conocimientos científicos y experiencias clínicas en el manejo del cáncer. Este congreso representa una ventana abierta hacia los avances más recientes en el diagnóstico y tratamiento del cáncer, así como hacia los desafíos y oportunidades que enfrentamos en nuestra labor diaria. Será una ocasión propicia para aprender de los líderes de opinión nacionales e internacionales en el campo de la oncología, compartir nuestras experiencias y establecer colaboraciones que puedan tener un impacto significativo en la vida de nuestros pacientes.

Agradecemos profundamente a todos los conferencistas, investigadores, patrocinadores y asistentes por su participación y contribución a este congreso. Su presencia y compromiso demuestran la dedicación y pasión que compartimos por el avance de la ciencia oncológica y la mejora de la calidad de vida de los pacientes.

En nombre del comité organizador, deseamos que este congreso sea una experiencia enriquecedora y transformadora para todos ustedes. Esperamos que las presentaciones y discusiones sean inspiradoras, que los vínculos se fortalezcan y que las ideas compartidas se conviertan en acciones concretas para mejorar la atención oncológica en nuestro país y más allá.

Bienvenidos al Congreso Científico Best of ASCO en Lima, Perú.  
¡Juntos, estamos un paso más cerca de un futuro sin cáncer!

## FACULTY



**PAOLA CATHERINE MONTENEGRO BELTRÁN MD  
PRESIDENT**

**JOSÉ CARLOS REVILLA LÓPEZ MD  
VICE PRESIDENT**

**CARLOS HUGO ALIAGA MACHA MD  
GENERAL SECRETARY**

**EDUARDO AUGUSTO PAZ CORNEJO MD  
CHAIRMAN OF SCIENTIFIC AFFAIRS**

**REBECA AZUCENA SERRA JARAMILLO MD  
FINANCE SECRETARY**

**RODRIGO AUQUI FLORES MD  
SECRETARY OF AFFILIATES**

**FERNANDO SEGUNDO VALENCIA JUAREZ MD  
CHAIRMAN OF INTERNAL AFFAIRS**

**ROSDALI YESENIA DÍAZ CORONADO MD  
CHAIRMAN ETHICS COMMITTEE**

## SPEAKERS

ANDRES CARDONA MD	
CARLOS ALIAGA MD	
CARLOS DESPOSORIO MD	
CARMEN PUPARELI MD	
EDUARDO PAZ MD	
ERIKA RUIZ MD	
FERNANDO VALENCIA MD	
HENRY GOMEZ MD	
HUGO FUENTES MD	
JORGE LEÓN MD	
JUAN CARLOS HARO MD	
JULE VÁSQUEZ MD	
LOURDES LÓPEZ MD	
MARC EDY PIERRE MD	
MILENA VILLARROEL MD	
MIVAELO OLIVERA MD	
OLIVER RUA MD	
OSCAR ARRIETA MD	
PEDRO BARATA MD	
REBECA SERRA MD	
SILVIA NECIOSUP MD	
THANYA RUNCIMAN MD	
VALERIA CÁCERES MD	

JUNE 23

# DAY 1

8:50-9:00 h

OPENING

PAOLA MONTENEGRO MD

9:00-9:25 h

DEVELOPMENTAL THERAPEUTICS—IMMUNOTHERAPY

Eduardo Paz MD | PERU  
Speaker —

Moderator: José Carlos Revilla MD

- Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.
- Evaluation of change in RECIST tumor size and survival in patients with rare cancers treated with checkpoint inhibitor therapy (SWOG S1609).
- Clinical and immune phenotypes associated with immune checkpoint inhibitor-induced autoimmune diabetes.
- First-line treatment of fecal microbiota transplantation for immune-mediated colitis.

9:25-9:50 h

DEVELOPMENTAL THERAPEUTICS—MOLECULARLY  
TARGETED AGENTS AND TUMOR BIOLOGY

Carlos Aliaga MD | PERU  
Speaker —

Moderator: José Carlos Revilla MD

- Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.
- Detection of peritoneal metastases during cytoreductive surgery using pegsitacianine, a pH sensitive imaging agent: Final results from a phase 2 study.

- Methylated DNA biomarkers and incident cancer in the American Cancer Society (ACS) Cancer Prevention Study-3 (CPS-3) cohort.
- Safety and efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid and CNS tumors: Results from a phase 1/2a study.

9:50-10:15 h

## CARE DELIVERY AND REGULATORY POLICY

**Rebeca Serra MD | PERU**

Speaker —

**Moderator: José Carlos Revilla MD**

- Childhood leukemia survival in the US-Mexico border: Building sustainable leukemia care using health systems strengthening models.
- Large-scale observational prospective cohort study of a multi-cancer early detection (MCED) test in symptomatic patients referred for cancer investigation.
- Prior authorizations for oral anticancer drugs and delayed prescription fills.
- A cognitive behavioral digital therapeutic for anxiety and depression in patients with cancer: A decentralized randomized controlled trial.

10:15-10:35 h

## SARCOMA

**Juan Carlos Haro MD | PERU**

Speaker —

**Moderator: Víctor Castro MD**

- A multicenter phase II study of cabozantinib + nivolumab for patients (pts) with advanced angiosarcoma (AS) previously treated with a taxane (Alliance A091902).
- Overall survival and long-term safety in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: Updated analyses from INTRIGUE.

10:35-10:50 h

## QUESTIONS AND ANSWERS

10:50-11:10 h

## BREAK

11:10-11:35 h

## CENTRAL NERVOUS SYSTEM TUMORS

**Fernando Valencia MD | PERU**  
Speaker —

**Moderator: Victor Castro MD**

- INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
- Clinical and analytical validation of a targeted gene expression biomarker predicting meningioma outcomes and radiotherapy responses.
- External validation and nomogram for risk factors of CNS metastasis in patients with clinically localized melanoma.
- Belzutifan treatment for von Hippel-Lindau (VHL) disease-associated central nervous system (CNS) hemangioblastomas (HBs) in the phase 2 LITESPARK-004 study.

11:35-11:55 h

## HEMATOLOGIC MALIGNANCIES - LEUKEMIA

**Lourdes López MD | PERU**  
Speaker —

**Moderator: Luis Casanova MD**

- Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.
- Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naïve transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).

11:55-12:20 h

## HEMATOLOGIC MALIGNANCIES - LYMPHOMA

**Thanya Runciman MD | PERU**

Speaker —

**Moderator: Luis Casanova MD**

- SWOG S1826, a Randomized Study of Nivolumab (N) AVD versus Brentuximab Vedotin (BV) AVD in Advanced Stage (AS) Classic Hodgkin Lymphoma
- Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma.
- Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the LYMA trial, a LYSA study.
- Results of a phase 3 study of IVO vs IO for previously untreated older patients (pts) with chronic lymphocytic leukemia (CLL) and impact of COVID-19 (Alliance).

12:20-12:45 h

## HEMATOLOGIC MALIGNANCIES—PLASMA CELL DYSCRASIA

**Jule Vásquez MD | PERU**

Speaker —

**Moderator: Luis Casanova MD**

- First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma.
- First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
- Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and MRD results from an open-label randomized phase 3 study.
- Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.
- CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.

12:45-13:00 h

## QUESTIONS AND ANSWERS

13:00-14:20 h

## SYMPOSIUM MSD:

Revelando los datos del estudio KN - 826 para el tratamiento del cáncer cervicouterino: Pembrolizumab como tratamiento clave de la primera línea.

Speaker: **Marc Edy Pierre MD | COLOMBIA**

1430-14:55 h

## GYNECOLOGIC CANCER

**Marc Edy Pierre MD | COLOMBIA**

Speaker —

**Moderator: Atilio Romero MD**

- Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
- An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC). A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).
- Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.

14:55-15:20 h

## PEDIATRICS

**Milena Villarroel MD | CHILE**

Speaker —

**Moderator: Rosdali Díaz MD**

- Carvedilol for prevention of heart failure in anthracycline-exposed survivors of childhood cancer: Results from COG ALTE1621
- Genomic determinants of outcome in acute lymphoblastic leukemia: A Children's Oncology Group study

- High risk neuroblastoma (HR-NB) with MNA and age <18 months: Results from the HR-NBL1/SIOPEN trial.
- A multicenter cooperative group study of late effects after high-risk neuroblastoma: COG ALTE15N2—LEAHRN study

15:20-15:45 h

## GENITOURINARY CANCER—KIDNEY AND BLADDER

**Carlos Desposorio MD | PERU**  
Speaker —

**Moderator: Milagros Huaranga MD**

- Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study.
- Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial.
- SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer.
- Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

15:45-16:00 h

## QUESTIONS AND ANSWERS

16:00-16:20 h

## CEREMONIA DE RECONOCIMIENTO: CARLOS VALLEJOS MD

16:20-16:40 h

## BREAK

16:40-17:05 h

## GENITOURINARY CANCER—PROSTATE, TESTICULAR, AND PENILE

**Pedro Barata MD | USA**

Speaker —

**Moderator: Milagros Huaranga MD**

- Prostate irradiation in men with de novo, low-volume, metastatic, castration-sensitive prostate cancer (mCSPC): Results of PEACE-1, a phase 3 randomized trial with a 2x2 design.
- Prognostic impact of PSA nadir ( $n$ )  $\geq 0.1$  ng/mL within 6 months ( $m$ ) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.
- TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.
- Long term follow-up analysis of plasma miR371 expression to detect early relapse in patients with clinical stage I testicular germ cell tumors on surveillance.

17:05-17:10 h

## QUESTIONS AND ANSWERS

17:10-18:10 h

## SYMPOSIUM BAYER

Actualización en el manejo del CPHSm con el uso del triplete como nuevo estandar de tratamiento.

Speaker: **Silvia Neciosup MD | PERU**

18:10-19:10 h

## SYMPOSIUM TECNOFARMA

Actualización en el manejo del carcinoma urotelial avanzado.

Speaker: **Pedro Barata MD | USA**



JUNE 24

# DAY 2

8:30-8:55 h

## SYMPTOMS & SURVIVORSHIP

**Oliver Rua MD | PERU**  
Speaker —

**Moderator: Rodrigo Auqui MD**

- A multicenter randomized controlled trial (RCT) for the effectiveness of Comprehensive Geriatric Assessment (CGA) with extensive patient coaching on quality of life (QoL) in older patients with solid tumors receiving systemic therapy: G-oncoCOACH study.
- Effect of a telephone-based weight loss intervention (WLI) on weight at 12-months in women with early breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.
- Reduced symptom burden after implementation of an electronic symptom management program.
- Telehealth-based psychological intervention for caregivers of patients with primary malignant brain tumors: A randomized controlled trial.

8:55-9:20 h

## GASTROINTESTINAL CANCER—COLORECTAL AND ANAL

**Erika Ruiz MD | MEXICO**  
Speaker —

**Moderator: Alejandro Figueroa MD**

- PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).
- Efficacy of panitumumab in patients with left-sided disease, MSS/MSI-L, and RAS/BRAF WT: A biomarker study of the phase III PARADIGM trial.
- Sustained organ preservation in rectal cancer patients treated with total neoadjuvant therapy: Long-term results of the OPRA trial.
- HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS.

## GASTROINTESTINAL CANCER—GASTROESOPHAGEAL, PANCREATIC, AND HEPATO BILIARY

9:20-9:45 h

**Jorge León MD | PERU**

Speaker —

**Moderator: Alejandro Figueroa MD**

- Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC).
- Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors.
- Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial.

9:45-10:00 h

### QUESTIONS AND ANSWERS

10:00-11:00 h

## SYMPOSIUM MSD

**Moderator: Luis Mas MD**

Contexto del abordaje multidisciplinario de estadios tempranos en el Perú: cifras, oportunidades y desafíos.

Speaker: **Edgar Amorin MD | PERU**

Un nuevo horizonte en el tratamiento del CPCNP:  
El poder de Pembrolizumab en la terapia adyuvante.

Speaker: **Oscar Arrieta MD | MEXICO**

11:00-11:15 h

### BREAK

## LUNG CANCER—NON-SMALL CELL LOCAL-REGIONAL/ SMALL CELL/OTHER THORACIC CANCERS

11:15-11:40 h

**Oscar Arrieta MD | MEXICO**

Speaker —

**Moderator: Luis Mas MD**

- KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
- OS survival analysis from the ADURA trial of adjuvant osimertinib in patients with resected EGFR-mut stage 1B-IIIA NSCLC
- Final survival data from a randomized phase II trial comparing high-dose with standard-dose twice-daily (BID) thoracic radiotherapy (TRT) in limited stage small-cell lung cancer (LS SCLC).
- IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (Pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.

11:40-11:50 h

## QUESTIONS AND ANSWERS

12:00-13:20 h

## SYMPOSIUM BRISTOL

El impacto de la inmunoterapia en Neoadyuvancia y estadios avanzados del CPCNP

Speaker: Camen Pupareli MD | ARGENTINA

13:20-14:20 h

## SYMPOSIUM ASTRAZENECA

Cáncer de pulmón EGFRm: El legado de la medicina de precisión

Speaker: Andrés Cardona MD | COLOMBIA

14:30-14:55 h **LUNG CANCER—NON-SMALL CELL METASTATIC**

---

**Camen Pupareli MD | ARGENTINA**  
Speaker —

**Moderator: Luis Mas MD**

- Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.
- TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).
- Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.
- The primary endpoint analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in advanced non-squamous, non-small cell lung cancer patients with KRAS G12C mutation (WJOG14821L).
- 

14:55-15:20 h **HEAD AND NECK CANCER**

---

**Mivael Olivera MD | PERU**  
Speaker —

**Moderator: Luis Mas MD**

- PD-1 blockade with Sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): a multicenter, phase 3, randomized controlled trial (CONTINUUM)
- Neoadjuvant nivolumab, paclitaxel, and carboplatin followed by response-stratified chemoradiation in locoregionally advanced HPV negative head and neck squamous cell carcinoma (HNSCC): The DEPEND trial.

- Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.
- Dose expansion results of the bifunctional EGFR/TGF $\beta$  inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.

15:20-15:45 h

## MELANOMA/SKIN CANCERS

**Hugo Fuentes MD | PERU**

Speaker —

**Moderator: Carlos Castañeda MD**

- Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.
- Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.
- Non-comparative, open-label, international, multicenter phase I/II study of nivolumab (NIVO)  $\pm$  ipilimumab (IPI) in patients (pts) with recurrent/metastatic Merkel cell carcinoma (MCC) (CheckMate 358).
- The impact of response-directed surgery and adjuvant therapy on long-term survival after neoadjuvant ipilimumab plus nivolumab in stage III melanoma: Three-year data of PRADO and OpACIN-neo.

15:45-16:00 h

## QUESTIONS AND ANSWERS

**CEREMONIA DE RECONOCIMIENTO:  
LUIS CASANOVA MD**

16:00-16:20 h

**BREAK**

16:30-16:55 h

## BREAST CANCER—METASTATIC

**Henry Gomez MD | PERU**  
Speaker —

**Moderator: Carlos Castañeda MD**

- Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC).
- Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.
- Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).
- An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.

16:55-17:20 h

## BREAST CANCER—LOCAL/REGIONAL/ADJUVANT

**Valeria Cáceres MD | ARGENTINA**  
Speaker —

**Moderator: Carlos Castañeda MD**

- Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer.
- Efficacy and safety results by age in monarche: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
- Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials.
- Outcomes according to treatment received for small node-negative HER2+ breast tumors in the Surveillance, Epidemiology, and End Results (SEER) database, 2010-2019.

17:20-17:30 h

## QUESTIONS AND ANSWERS

---

17:30-18:30 h

## SYMPOSIUM SIEGFRIED

---

Últimos avances sobre inhibidores de ciclinas en adyuvancia y su impacto en la práctica clínica.

Speaker: **Henry Gómez MD | PERU**

18:30-19:30 h

## SYMPOSIUM TECNOFARMA

---

Inhibidores CDK 4/6 en cáncer de mama luminal temprano.

Speaker: **Valeria Cáceres MD | ARGENTINA**

## CLAUDIA

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

**BEST OF ASCO®**  
OFFICIALLY LICENSED

**BEST OF ASCO®**  
OFFICIALLY LICENSED

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

**BEST OF ASCO®**  
OFFICIALLY LICENSED

**BEST OF ASCO®**  
OFFICIALLY LICENSED

**BEST OF ASCO®**  
OFFICIALLY LICENSED

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

**BEST OF ASCO®**  
OFFICIALLY LICENSED

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

---

BEST OF ASCO<sup>®</sup>  
OFFICIALLY LICENSED

**BEST OF ASCO®**  
OFFICIALLY LICENSED

**BEST OF ASCO®**  
OFFICIALLY LICENSED

**BEST OF ASCO®**  
OFFICIALLY LICENSED



## **PERUVIAN SOCIETY OF MEDICAL ONCOLOGY**



### **INFORMATION**

---

PJE. PABLO LUNA 104, SAN BORJA SUR 949, OF. 702, SAN BORJA  
TELEPHONE: 997 930 727  
[SPOM@SPOMEDICA.ORG](mailto:SPOM@SPOMEDICA.ORG)  
[WWW.SPOMEDICA.ORG](http://WWW.SPOMEDICA.ORG)